The mechanism of the effect of ATO on NSCLC cells through a P62/mutant EGFR/autophagy axis allows us to foresee a new paradigm of the roles of arsenic in treating malignancies by targeting the regulatory pathways to promote the turnover of molecules of key pathological importance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.